Deal notes
Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.
Transaction overview
01Lexaria Bioscience Corp. announced a $5.9M warrant exercise / inducement at $12.92 per warrant exercised. H.C. Wainwright & Co. acted as exclusive placement agent for the financing.
- Financing type
- Warrant Exercise / Inducement
- Announcement date
- Sep 8, 2026
- Agreement date
- Sep 7, 2026
- Pricing date
- —
- Closing date
- —
- Filing date
- Sep 9, 2026
- Status
- Priced
- Market cap before announcement
- $23.4M
- Prior closing price
- $14.15
- Raise as % of market cap
- 25.2%
Market data · FMP
- Historical market cap
- $23,400,251
- Market date
- Sep 4, 2026
- Closing price
- $14.15
- Latest reported shares outstanding
- 1,652,496
- Latest reported float shares
- 1,602,575
- Share-data date
- Sep 30, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 1, 2026.
Financial Modeling Prep ↗Financing terms
02Warrant exercise / inducement
- Warrants exercised
- 453,969
- Original exercise price
- Varies by original cohort
- Exercise price paid
- $12.92
- Cash proceeds
- $5.9M
Original warrant cohorts
February 2024
- Originally issued
- Feb 16, 2024
- Original exercise price
- $32.78
- Exercised from this cohort
- —
October 2024
- Originally issued
- Oct 16, 2024
- Original exercise price
- $45.90
- Exercised from this cohort
- —
September 2025
- Originally issued
- Sep 29, 2025
- Original exercise price
- $20.55
- Exercised from this cohort
- —
December 2025
- Originally issued
- Dec 16, 2025
- Original exercise price
- $17.85
- Exercised from this cohort
- —
453,969 existing warrants in aggregate; allocation of exercised warrants among the four historical cohorts is not disclosed in this filing.
Series A investor warrants
- Warrant shares
- 453,969
- Cash exercise price
- $12.67
- Term
- Five years from the Effective Date defined in the Inducement Letter; immediately exercisable.
- Initial exercisability
- —
- Beneficial ownership limits
- —
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
Series B investor warrants
- Warrant shares
- 453,969
- Cash exercise price
- $12.67
- Term
- Eighteen months from the Effective Date defined in the Inducement Letter; immediately exercisable.
- Initial exercisability
- —
- Beneficial ownership limits
- —
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
Placement agent warrants
- Warrant shares
- 15,889
- Cash exercise price
- $16.15
- Term
- Five years from the Effective Date defined in the Letter Agreement, extended to the next Trading Day if necessary.
- Initial exercisability
- —
- Beneficial ownership limits
- —
Compensation warrants are excluded from investor warrant coverage.
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
Fees & transaction economics
03- Placement agent / underwriting fee
- 7%
- Agent fee amount
- $413,000
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
5900000
gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 millionOriginal source ↗
453,969 existing warrants in aggregate; allocation of exercised warrants among the four historical cohorts is not disclosed in this filing.
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
FMP reported market cap; as of 2026-09-04.
{"provider": "FMP", "symbol": "LEXX", "date": "2026-09-04", "marketCap": 23400251}Original source ↗
453969
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
12.67
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
5
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
Five years from the Effective Date defined in the Inducement Letter; immediately exercisable.
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
453969
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
12.67
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
1.5
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
Eighteen months from the Effective Date defined in the Inducement Letter; immediately exercisable.
In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue: (i) new unregistered Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of five (5) years from the Effective Date (as defined in the Inducement Letter); and (ii) new unregistered short-term Series B Common Stock purchase warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of Common Stock, which Series B Warrants will have an exercise price of $12.67 per share, will be immediately exercisable and will have a term of eighteen (18) months from the Effective Date.Original source ↗
15889
warrants to purchase up to 15,889 shares of Common Stock at an exercise price of $16.15 per shareOriginal source ↗
16.15
warrants to purchase up to 15,889 shares of Common Stock at an exercise price of $16.15 per shareOriginal source ↗
5
on the date that is the five (5) year anniversary of the Effective Date (as defined in the Letter Agreement), provided that, if such date is not a Trading Day, the date that is the immediately following Trading Day (the “ Termination Date ”)Original source ↗
Five years from the Effective Date defined in the Letter Agreement, extended to the next Trading Day if necessary.
on the date that is the five (5) year anniversary of the Effective Date (as defined in the Letter Agreement), provided that, if such date is not a Trading Day, the date that is the immediately following Trading Day (the “ Termination Date ”)Original source ↗
2024-02-16
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
32.78
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
2024-10-16
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
45.9
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
2025-09-29
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
20.55
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
2025-12-16
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗
17.85
The Existing Warrants were originally issued to the Holders on February 16, 2024, with an original exercise price of $32.78 per share, on October 16, 2024, with an original exercise price of $45.90 per share, on September 29, 2025, with an original exercise price of $20.55 per share, and on December 16, 2025, with an original exercise price of $17.85 per share. Pursuant to the Inducement Letters, such Holders immediately exercised their respective outstanding Existing Warrants to purchase up to an aggregate of 453,969 shares of Common Stock, at a reduced exercise price of $12.92 per share. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $5.9 million, prior to deducting placement agent fees and estimated offering expenses.Original source ↗